Exabis Library
Welcome to the e-CCO Library!
DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in Ulcerative Colitis patients
2017
ECCO'17 Barcelona
1
DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in ulcerative colitis patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP075: Colonic gamma delta t-cells respond innately to NKG2D ligands and are grossly dysregulated in active inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: Subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn' Disease
2017
ECCO'17 Barcelona
1
DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel
2016
ECCO'16 DOP
1
DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP076: A Danish cross-sectional study: Autoimmune and chronic inflammatory disorders associated with Ulcerative Colitis.
2016
ECCO'16 DOP
1
DOP076: A Danish cross-sectional study: autoimmune and chronic inflammatory disorders associated with ulcerative colitis.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP076: A Phase 2B, multicenter, randomised, placebo-controlled dose-ranging trial of peficitinab, an OralL JAK Inhibitor, in patients with moderately to severely active Ulcerative Colitis
2017
ECCO'17 Barcelona
1
DOP076: A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP076: IL-3 drives IL-10-secreting Tr1 cells to counteract experimental colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP077: Deep immunophenotyping reveals a role for Mucosal Associated Invariant T (MAIT) cells in the response to anti-TNF treatment in Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP077: Deep Immunophenotyping reveals a role for Mucosal Associated Invariant T (MAIT) cells in the response to anti-TNF treatment in Crohn’s Disease
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP077: Immunochip Analysis Identifies Multiple Susceptibility Loci for Collagenous Colitis
2016
ECCO'16 DOP
1
DOP077: Immunochip analysis identifies multiple susceptibility loci for collagenous colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP077: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP078: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP078: Risk of malignancy in paediatric inflammatory bowel disease: Results from the DEVELOP registry
2016
ECCO'16 DOP
1